家族性良性天疱疮患者ATP2C1基因突变研究

目的 探讨3个家族性良性天疱疮家系和1例散发患者的ATP2C1基因突变。方法 采取家系中患病成员外周血,应用外周血细胞DNA抽提、PCR扩增和DNA直接测序等方法检测ATP2C1基因突变情况,用反向测序验证突变,用100例无血缘关系个体作正常人对照。结果 在2个家族性良性天疱疮家系和1例散发患者中发现3个未曾报道的错义突变。家系1第20外显子2048位碱基G→A,导致错义突变R619K;家系2第8外显子853位碱基A→C,导致错义突变T221P;散发患者第23外显子2323位碱基T→C,导致错义突变Y711H。家系中非患病成员和100例无血缘关系正常人均未发现这些改变。在1个家族性良性天疱疮家系未检测到基因突变。结论 发现家族性良性天疱疮3种新的ATP2C1基因突变位点。     

慢性家族性良性天疱疮五家系ATP2C1基因突变分析

目的：检测中国汉族慢性家族性良性天疱疮5家系ATP2C1基因突变情况。方法：提取5家系中12例患者、13名表型正常及100名正常对照外周血基因组DNA，经PCR扩增后进行DNA测序，并使用Chromas软件解析。结果：家系1中3例患者存在ATP2C1基因第18号外显子c.1738A>G（p.I580V）突变，家系2 中2例患者存在ATP2C1基因第25号外显子c.2416C>T(p.R806*)突变，家系3中3例患者存在ATP2C1基因第15号外显子c.1250G>A（p.R417K）突变，家系4和家系5 中ATP2C1基因未发现突变。上述家系内表型正常个体及100名正常对照中均未检测到相应突变。结论：ATP2C1基因突变可能在3例汉族HHD家系内发挥致病作用。     

一婴儿期发病的慢性家族性良性天疱疮家系ATP2C1基因突变研究

目的 对一慢性家族性良性天疱疮家系进行测序,寻找ATP2C1基因外显子上的突变点,丰富关于ATP2C1基因突变的信息。方法 提取一慢性家族性良性天疱疮家系中先证者及包括其父母、舅舅在内的家族中6名其他成员的外周血DNA进行测序,与人类基因组ATP2C1序列相比较找出突变点,另外测50例正常人血的ATP2C1基因,除外单核苷酸多态性。结果 家系中先证者、其舅舅及其母亲在ATP2C1的第9外显子上存在一杂合性的剪切突变,第699位缺失腺嘌呤（A）,导致其下游第12位的氨基酸序列出现终止密码TGA。反向测序亦证实该突变。该家系中先证者父亲、其他3名成员及50例正常人均未见该突变。结论 本研究慢性家族性良性天疱疮家系中先证者及其母亲及舅舅ATP2C1的第9外显子上存在一杂合性的剪切突变,突变来自于母系并向下遗传。     

家族性良性天疱疮ATP2C1基因突变研究

目的 探讨家族性良性天疱疮5个散发病例的ATP2C1基因突变.方法 5例来自门诊的散发病例,采集外周血,提取基因组DNA,采用PCR和DNA直接测序的方法,检测5个散发家族性良性天疱疮患者的ATP2C1基因突变,在100例正常人对照中予以验证.结果在5例具有典型临床表现,经皮肤病理和免疫病理确诊的散发家族性良性天疱疮患者,检测到5个未曾报道的ATP2C1基因突变位点,包括1个缺失突变(2025delG),3个错义突变(L269R,C348R,A651D),和1个无义突变(Q259x).100例正常人对照中均未检测到上述突变.结论 发现家族性良性天疱疮新的ATP2C1基因突变位点.     

家族性良性天疱疮ATP2C1基因突变研究

目的 探讨家族性良性天疱疮5个散发病例的ATP2C1基因突变.方法 5例来自门诊的散发病例,采集外周血,提取基因组DNA,采用PCR和DNA直接测序的方法,检测5个散发家族性良性天疱疮患者的ATP2C1基因突变,在100例正常人对照中予以验证.结果在5例具有典型临床表现,经皮肤病理和免疫病理确诊的散发家族性良性天疱疮患者,检测到5个未曾报道的ATP2C1基因突变位点,包括1个缺失突变(2025delG),3个错义突变(L269R,C348R,A651D),和1个无义突变(Q259x).100例正常人对照中均未检测到上述突变.结论 发现家族性良性天疱疮新的ATP2C1基因突变位点.     

家族性良性天疱疮基因突变研究

目的 探讨家族性良性天疱疮17个先证者的ATP2C1基因突变。方法 采用PCR和DNA直接测序的方法，检测17个家族性良性天疱疮先证者的ATP2C1基因外显子区。结果 在9个先证者中检测到8个不同的ATP2C1基因突变位点，包括3个缺失突变（nt1464-1487／1462-1485del，1523delAT和2375delTTGT），3个剪接位点突变（360-2A→G，1415-2A→T和2243＋2T→C）及2个错义突变（P307L和D648Y）。120例正常人对照中均未检测到上述几种突变。结论 此8个ATP2C1基因突变是该病新的特异突变。     

家族性良性天疱疮ATP2C1基因突变研究

目的 探讨家族性良性天疱疮5个散发病例的ATP2C1基因突变。方法 5例来自门诊的散发病例,采集外周血,提取基因组DNA,采用PCR和DNA直接测序的方法,检测5个散发家族性良性天疱疮患者的ATP2C1基因突变,在100例正常人对照中予以验证。结果 在5例具有典型临床表现,经皮肤病理和免疫病理确诊的散发家族性良性天疱疮患者,检测到5个未曾报道的ATP2C1基因突变位点,包括1个缺失突变（2025delG）,3个错义突变（L269R,C348R,A651D）,和1个无义突变（Q259X）。100例正常人对照中均未检测到上述突变。结论 发现家族性良性天疱疮新的ATP2C1基因突变位点。     

一个家族性良性天疱疮致病基因的新突变位点

目的 对一个中国人家族性良性天疱疮（HHD）家系进行ATP2C1基因突变检测。方法 调查一个HHD家系3代9人,其中2例具有HHD的临床表现。收集该家系所有成员的外周血,提取基因组DNA,采用PCR扩增ATP2C1基因的27个外显子,用直接测序法进行DNA测序分析。同时设立100例无亲缘关系的正常人作为对照。 结果 在该家系的2例患者中均检测到1个尚未报道过的ATP2C1基因错义突变位点（M 661 R）。在该家系健康个体及无亲缘关系的正常对照均未发现相同突变。结论 在该HHD家系中发现ATP2C1基因一个新的特异性突变位点（M 661 R）。     

家族性良性慢性天疱疮基因诊断1例

目的:检测一家族性良性慢性天疱疮患者子代ATP2C1基因突变.方法: 应用DNA直接测序的方法对一已经检测到基因突变的家族性良性慢性天疱疮患者的子代进行突变检测,以对患者第三代进行产前咨询.结果:在其子代未发现相同的突变位点.结论: 可以预测患者第三代不会患有家族性良性慢性天疱疮.     

家族性慢性良性天疱疮ATP2C1基因突变分析

目的探讨家族性慢性良性天疱疮(Hailey-Hailey disease,HHD)患者ATP2C1基因的突变情况。方法应用外周血DNA抽提、PCR和DNA直接测序等方法对中国非同族的2个HHD家系和2例散发患者的ATP2C1基因的27个外显子进行突变检测,并利用Pubmed和中国学术文献网络出版总库检索最近12年来国内外有关HHD患者ATP2C1基因突变分析的文献,统计分析结果。结果入组者发现1例剪切突变118-2A→G,1例错义突变K866T,1例无义突变S212X和1例缺失移码突变356fs2X。综述文献发现ATP2C1基因突变主要集中于3个功能区,此外还发现22外显子是亚洲人种HHD的高风险位点。结论这4例的突变方式目前国内外尚未见报道,可影响转录和翻译的结果,是造成相应家系和散发患者临床病变的特异突变。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.